These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Intermittent intravenous immunoglobulin infusion prevented relapses in patients with remission-exacerbation type chronic inflammatory demyelinating polyradiculoneuropathy]. Kanda F; Sekiguchi K; Oishi K; Hamaguchi H; Mitsui S; Kobessho H; Higuchi M; Shirafuji T; Ishihara H Rinsho Shinkeigaku; 2006 Mar; 46(3):236-8. PubMed ID: 16642939 [TBL] [Abstract][Full Text] [Related]
6. Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders. Markvardsen LH; Christiansen I; Harbo T; Jakobsen J Eur J Neurol; 2014; 21(1):147-52. PubMed ID: 24180709 [TBL] [Abstract][Full Text] [Related]
7. [Present status of high-dose intravenous immunoglobulin therapy and the future prospects ]. Kawasugi K Nihon Rinsho Meneki Gakkai Kaishi; 2003 Jun; 26(3):87-95. PubMed ID: 12868126 [No Abstract] [Full Text] [Related]
8. Corticosteroids can help distinguish between Guillain-Barré syndrome and first attack of chronic inflammatory demyelinating neuropathy: an illustrative case report. Alexander KJ; Alshubaili AF; Santhamoorthy P; Sharafuddin KM Med Princ Pract; 2008; 17(5):422-4. PubMed ID: 18685286 [TBL] [Abstract][Full Text] [Related]
9. Individual patients who experienced both Guillain-Barré syndrome and CIDP. Kuitwaard K; van der Pol WL; Ruts L; van Doorn PA J Peripher Nerv Syst; 2009 Mar; 14(1):66-8. PubMed ID: 19335542 [No Abstract] [Full Text] [Related]
10. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. Choudhary PP; Hughes RA QJM; 1995 Jul; 88(7):493-502. PubMed ID: 7633875 [TBL] [Abstract][Full Text] [Related]
11. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease. Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654 [TBL] [Abstract][Full Text] [Related]
12. [Adverse effects of intravenous human polyvalent immunoglobulins]. Chapuis C; Guy N; Besson G Rev Neurol (Paris); 2008 Sep; 164 Spec No 3():F203-10. PubMed ID: 18992580 [No Abstract] [Full Text] [Related]
13. Acute motor response following a single IVIG treatment course in chronic inflammatory demyelinating polyneuropathy. Harbo T; Andersen H; Jakobsen J Muscle Nerve; 2009 Apr; 39(4):439-47. PubMed ID: 19229876 [TBL] [Abstract][Full Text] [Related]
14. Acquired inflammatory demyelinating neuropathies. Ensrud ER; Krivickas LS Phys Med Rehabil Clin N Am; 2001 May; 12(2):321-34, ix. PubMed ID: 11345010 [TBL] [Abstract][Full Text] [Related]
15. The Role of Immunoglobulin in the Treatment of Immune-Mediated Peripheral Neuropathies. Tobon A J Infus Nurs; 2017; 40(6):375-379. PubMed ID: 29112586 [TBL] [Abstract][Full Text] [Related]
19. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Dalakas MC Neurology; 2002 Dec; 59(12 Suppl 6):S13-21. PubMed ID: 12499466 [TBL] [Abstract][Full Text] [Related]
20. Haemolytic anaemia associated with high dose intravenous immunoglobulin therapy in a child with Guillain-Barré syndrome. Trifa M; Simon L; Hamza J; Bavoux F; des Roziers NB Arch Dis Child; 2003 Sep; 88(9):836-7. PubMed ID: 12937119 [No Abstract] [Full Text] [Related] [Next] [New Search]